Countries Request a quote
GHRP-2 — Alphagenics vial
Growth Hormone

GHRP-2

Pralmorelin · KP-102

GH-releasing hexapeptide, GHS-R1a agonist

Molecular weight818.0 g/mol
CAS158861-67-7
Length6 amino acids
Available presentations
Certificate of analysis (COA)
5mg
Request a quote Quick guide Research protocol View evidence Reconstitution calculator Physician login

About GHRP-2

GHRP-2 (pralmorelin) is a synthetic hexapeptide from the family of growth hormone-releasing peptides, developed from the pioneering work of Cyril Bowers.

It acts on the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary and is one of the most potent GH secretagogues in its class. In Japan it has been used as a diagnostic agent for GH deficiency in adults.

Quick guide · 5 key points

GHRP-2: a potent GH releaser

GHRP-2 is a synthetic hexapeptide that triggers growth hormone (GH) release through the ghrelin receptor. Here are five things the research shows.

View research protocolProtocol (PDF) Open guide (PDF) Download guide
  1. 1

    More GH release than GHRH itself

    GHRP-2 is a synthetic agonist of the ghrelin receptor, the same receptor the appetite hormone acts on. In 6 healthy young adults, intravenous GHRP-2 was associated with a GH release greater than that of GHRH, and greater still at the higher dose.1,2

    > GHRHGH response in healthy young adults
  2. 2

    A diagnostic test for GH deficiency

    In a Japanese study of 58 patients with severe GH deficiency and 77 healthy subjects, one intravenous dose of GHRP-2 brought peak GH to 84.6 µg/L in healthy subjects vs 1.36 µg/L in patients, with good reproducibility. The test has been shown to tell the two groups apart with high reliability.3

    84.6 vs 1.36µg/L peak GH: healthy subjects vs patients
  3. 3

    More appetite, as with ghrelin

    In 7 lean, healthy men, a GHRP-2 infusion was associated with a 35.9% increase in food intake at a free buffet compared with saline. Every participant ate more, similar to what has been reported with ghrelin.2

    +35.9%Buffet food intake, vs saline
  4. 4

    Active by the nasal route, too

    In 15 children with short stature, 6 months of intranasal GHRP-2 was associated with growth velocity rising from 3.7 to 6.1 cm/year, a modest but significant increase. It was well tolerated.4

    3.7 → 6.1cm/year growth velocity at 6 months
  5. 5

    Not fully selective

    GHRP-2 is not fully specific for GH: in healthy adults it has been associated with rises in prolactin, ACTH and cortisol. Its effect on ACTH and cortisol was similar to that of corticotropin-releasing hormone (CRH).1

    PRL · ACTH · cortisolHormones that also rise after a dose
References
  1. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-91. PMID 9285939
  2. Laferrère B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-4. PMID 15699539
  3. Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27. PMID 17609397
  4. Pihoker C, et al. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol. 1997;155(1):79-86. PMID 9390009

Structure and sequence

2D structure generated from PubChem CID 6918245

Sequence

DAlaD2NalAlaTrpDPheLysNH2

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Clinical study

    In a study with 58 patients with severe GH deficiency and 77 healthy subjects, the GHRP-2 stimulation test has shown a high ability to distinguish adults with severe GH deficiency from healthy subjects, with good reproducibility.

    Chihara K et al. Eur J Endocrinol. 2007;157:19-27 · PMID 17609397
  2. Clinical study

    In 7 lean, healthy men, subcutaneous GHRP-2 infusion has been associated with a 35.9% increase in caloric intake at an ad libitum buffet-style meal, compared with saline.

    Laferrère B et al. J Clin Endocrinol Metab. 2005;90:611-614 · PMID 15699539
  3. Clinical study

    In patients with prolonged critical illness, GHRP-2 infusion together with TRH has reactivated GH and TSH secretion and has been associated with a more anabolic metabolic profile.

    Van den Berghe G et al. J Clin Endocrinol Metab. 1999;84:1311-1323 · PMID 10199772
  4. Clinical study

    In children with short stature, intranasal administration of GHRP-2 has been associated with an increase in growth velocity.

    Pihoker C et al. J Endocrinol. 1997;155:79-86 · PMID 9390009
  5. Clinical study

    In healthy young adults, intravenous GHRP-2 has shown potent GH release, greater than that of GHRH and larger with the highest dose, accompanied by rises in prolactin (smaller than with TRH) and in ACTH and cortisol (similar to those with CRH).

    Arvat E et al. Peptides. 1997;18:885-891 · PMID 9285939

More in Growth Hormone

SermorelinIpamorelinTesamorelinGHRP-6